Literature DB >> 33635476

Clinicopathologic findings of chronic active Epstein-Barr virus infection in adults: A single-center retrospective study in China.

Jing Lin1, Haicong Wu1, Lei Gu2, Xia Wu1, Miaofang Su1, Haiyan Lin1, Bang Liu1, Jiaolong Zheng1, Xuan Mei1, Dongliang Li3.   

Abstract

Chronic active Epstein-Barr virus (CAEBV) infection is a rare disease with a high mortality rate. Our study aimed to summarize the clinicopathological characteristics of CAEBV infection in adults and improve knowledge of the disease. Data for 19 adult patients with CAEBV confirmed at our hospital from January 2010 to December 2019 were collected retrospectively. There were 14 males and 5 females, and the median age was 33 years (range 14-83). The main clinical manifestations included recurrent fever (84.2%, 16/19), splenomegaly (89.5%, 17/19), hepatomegaly (73.6%, 14/19), lymphadenopathy (42.1%, 8/19), abnormal liver function (78.9%, 15/19), hemopenia (94.7%, 18/19), and hemophagocytosis (52.6%, 10/19). A total of 22 specimens were collected from 19 patients for histopathology. Most of the biopsy specimens showed lymphocyte infiltration. Immunohistochemical staining and EBV-encoded small RNA (EBER) in situ hybridization were performed for 14 of the 22 samples. CD3 and CD20 staining were positive, with more CD3-positive cells than CD20-positive cells (100%, 14/14), and EBER in situ hybridization was positive in most cases (85.7%, 12/14). More than half of TCR gene rearrangement tests showed monoclonal rearrangement (66.6%, 4/6). Mortality was high, with most CAEBV patients dying during the period from diagnosis to the end of follow-up (12/19, 63%); the median survival time was only 20.75 months. Based on limited data, we consider that CAEBV is a disease with different ages of onset and is a complex and heterogeneous syndrome with features of both immunodeficiency and malignant neoplasms. Furthermore, the prognosis of adult-onset CAEBV appears to be very poor.

Entities:  

Keywords:  Adults; Chronic active EB virus infection; Clinical features; Pathology

Mesh:

Substances:

Year:  2021        PMID: 33635476     DOI: 10.1007/s10238-021-00689-w

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  18 in total

1.  Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Authors:  Ayako Arai; Ken-Ichi Imadome; Yuko Watanabe; Mayumi Yoshimori; Takatoshi Koyama; Takeharu Kawaguchi; Chiaki Nakaseko; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2011-04-14       Impact factor: 2.490

Review 2.  Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.

Authors:  N Abdel-Wahab; S Talathi; M A Lopez-Olivo; M E Suarez-Almazor
Journal:  Lupus       Date:  2017-09-24       Impact factor: 2.911

3.  Inflammatory cytokine production in chronic active Epstein-Barr virus infection.

Authors:  Erika Onozawa; Haruna Shibayama; Ken-Ichi Imadome; Akiho Tsuzura; Takatoshi Koyama; Osamu Miura; Ayako Arai
Journal:  Rinsho Ketsueki       Date:  2017

4.  EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.

Authors:  Hiroshi Kimura; Yoshinori Ito; Shinji Kawabe; Kensei Gotoh; Yoshiyuki Takahashi; Seiji Kojima; Tomoki Naoe; Shinichi Esaki; Atsushi Kikuta; Akihisa Sawada; Keisei Kawa; Koichi Ohshima; Shigeo Nakamura
Journal:  Blood       Date:  2011-11-16       Impact factor: 22.113

5.  Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.

Authors:  Ren-Ching Wang; Sheng-Tsung Chang; Yen-Chuan Hsieh; Wan-Ting Huang; Jeng-Dong Hsu; Chih-En Tseng; Ming-Chung Wang; Wei-Shou Hwang; John Wang; Shih-Sung Chuang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  Bilateral granulomatous panuveitis in two patients with T-cell type of chronic active Epstein-Barr virus infection.

Authors:  Hiroyuki Takahashi; Hiroshi Takase; Ayako Arai; Manabu Mochizuki; Kyoko Ohno-Matsui
Journal:  BMC Ophthalmol       Date:  2019-03-29       Impact factor: 2.209

Review 7.  Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory.

Authors:  Alan B Rickinson; Heather M Long; Umaimainthan Palendira; Christian Münz; Andrew D Hislop
Journal:  Trends Immunol       Date:  2014-03-01       Impact factor: 16.687

Review 8.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

9.  Altered ratio of circulating follicular regulatory T cells and follicular helper T cells during primary EBV infection.

Authors:  Jiang Qian; Qinhua Yu; Guoqing Chen; Mingxia Wang; Zhao Zhao; Yueyue Zhang; Liannv Qiu
Journal:  Clin Exp Med       Date:  2020-03-23       Impact factor: 3.984

10.  A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features.

Authors:  Keisuke Kawamoto; Hiroaki Miyoshi; Takaharu Suzuki; Yasuji Kozai; Koji Kato; Masaharu Miyahara; Toshiaki Yujiri; Ilseung Choi; Katsumichi Fujimaki; Tsuyoshi Muta; Masaaki Kume; Sayaka Moriguchi; Shinobu Tamura; Takeharu Kato; Hiroyuki Tagawa; Junya Makiyama; Yuji Kanisawa; Yuya Sasaki; Daisuke Kurita; Kyohei Yamada; Joji Shimono; Hirohito Sone; Jun Takizawa; Masao Seto; Hiroshi Kimura; Koichi Ohshima
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941

View more
  2 in total

1.  A rare B-cell type chronic active Epstein-Barr virus infection patient mimicking lymphoma on 18F-FDG PET/CT and literature review.

Authors:  Hao Jiao; Yongbai Zhang; Zhao Chen; Xueqi Chen; Yongkang Qiu; Wenpeng Huang; Lin Nong; Lei Kang
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-08-20

2.  Multisystem T-cell Chronic Active Epstein-Barr Virus Infection: From the Eye to the Kidney.

Authors:  Guillaume Vial; Laure Barthod; Sophie Schneider; Patrick Mercié; Pierre Duffau; Agathe Vermorel; Emmanuel Ribeiro
Journal:  Open Forum Infect Dis       Date:  2022-08-18       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.